Armis and Security Risk Advisors Announce Strategic Partnership
2.8.2023 15:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today announced a strategic partnership with international cybersecurity consulting firm, Security Risk Advisors (SRA). This collaboration empowers joint customers as both organizations leverage their respective areas of expertise to secure operational technology (OT) and protect cyber physical systems (CPS).
As operational technology continues to become more connected, the responsibility of monitoring and securing these assets is increasingly crucial to protect business continuity, supply chain, and consumers.
“We’re extremely proud to work with such incredible global partners, including SRA,” said Tim Mackie, Vice President Worldwide Channels, Biz Dev and Alliances, Armis. “SRA’s specialized security services combined with our technology and expertise immensely benefit our shared customers. We’re happy to formalize this partnership and to work closely together to better protect critical cyber physical systems.”
Armis offers the industry’s most comprehensive asset intelligence platform providing unified asset visibility and superior security for organizations that need to protect against unseen operational and cyber risks, increase efficiencies, optimize use of resources and safely innovate with new technologies to grow.
“The most likely cause for not getting product to patients is a potential incident where a cyberattack takes a plant down and renders the computer-driven devices unusable,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “We primarily deployed Armis for this use case—to improve our supply continuity and the resiliency of our overall manufacturing process. At Takeda, nothing comes before making sure that we get our medicines to patients, and Armis is one of the key contributors to making sure that we can do that.”
“Our mission is to help our clients build cybersecurity resilience in their CPS/OT ecosystem and our partnership with Armis helps with just that,” said Jason Rivera, Director, Cyber Physical Systems/OT Security, Security Risk Advisors. “This partnership with Armis enables us to better protect our clients by having a constant pulse on assets and potential risks to their environments. Their platform allows us to be more proactive about CPS/OT security measures and have a better reactive grasp on security events and incidents. We’re narrowing the gap between Armis’ industry-leading technology and organizations who need to grow their CPS/OT security capabilities.”
SRA is a member of the Armis Partner Experience (APEX) program. The mission of this program is to build long-term, strategic relationships between Armis and its partners, and to foster collaboration to serve customers in the best way possible. Apply here to become a partner.
Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/
To request an ICS Risk Assessment from Armis, please visit: https://www.armis.com/ics-security-risk-assessment/
To learn more about SRA’s Cyber Physical Systems security services, please visit: https://sra.io/cpss
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
About Security Risk Advisors
Security Risk Advisors (SRA) provides specialized security services including Penetration Testing, Purple Teams, Cloud Security, Resilience, Cyber Physical Systems Security, Engineering, and 24x7x365 Cybersecurity Operations. SRA’s mission is to “Level Up” every day to protect its clients and their customers. The company delivers security services to Fortune and Global 1000 companies, innovating technology startups, and mission-oriented non-profits. SRA is headquartered in Philadelphia, with offices in Rochester, NY and Kilkenny, Ireland.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802590955/en/
Contact information
Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
Doug Webster
Marketing Manager
SRA
info@sra.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
